BEIGF — BeOne Medicines Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1651308 ·
Switzerland
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,889,815,000 | 1,672,919,000 | 418,675,000 | 384,706,000 | 9,875,925,000 | 5,781,128,000 | 4,055,531,000 |
| Jun 2026 | 1,705,071,000 | 1,530,541,000 | 325,047,000 | 237,007,000 | 9,175,615,000 | 5,098,041,000 | 4,001,617,000 |
| Mar 2026 | 1,513,438,000 | 1,346,223,000 | 249,902,000 | 227,357,000 | 8,553,619,000 | 4,791,676,000 | 3,793,177,000 |
| Dec 2025 | 1,498,170,000 | 1,355,748,000 | 185,035,000 | 66,502,000 | 8,188,573,000 | 4,547,530,000 | 3,827,379,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,590,210,000
Investing CF
$-168,958,000
Financing CF
$261,703,000
CapEx
$-161,480,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.60
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-7,470,833,000
Inventory
$807,922,000
Receivables
$1,149,113,000
ST Investments
—
EBIT TTM
$1,310,054,000
Pretax Income TTM
$1,131,275,000
Interest Exp TTM
$131,397,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,606,494,208
EBITDA
$1,328,759,040
Free Cash Flow
$1,026,932,608
Enterprise Value
$28,868,691,968
Total Cash
$5,781,128,192
Total Debt
$2,061,346,944
Shares Out
1,369,883,771
Trailing EPS
$0.43
Book Value
$3.92
ROE
18.4%
ROA
8.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,343,033,000 | 447,136,000 | 286,933,000 | 8,188,573,000 | 3,827,379,000 | 4,361,194,000 | 1,127,580,000 |
| Dec 2024 | 3,810,241,000 | -568,199,000 | -644,786,000 | 5,920,910,000 | 2,588,688,000 | 3,332,222,000 | -140,631,000 |
| Dec 2023 | 2,458,779,000 | -1,207,736,000 | -881,708,000 | 5,805,275,000 | 2,267,948,000 | 3,537,327,000 | -1,157,453,000 |
| Dec 2022 | 1,415,921,000 | -1,789,665,000 | -2,003,815,000 | 6,379,290,000 | 1,995,935,000 | 4,383,355,000 | -1,496,619,000 |
TTM Snapshot
Revenues TTM
$6,128,963,000
NetIncome TTM
$655,707,000
OpCashFlow TTM
—
Assets (Latest)
$9,175,615,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
CLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL Community
2026-11-17 11:00 · Yahoo
Top 3 Healthcare Stocks To Watch In November 2026
2026-11-07 19:13 · Yahoo
BeOne Medicines Q3 Earnings Call Highlights
2026-11-06 13:14 · Yahoo
BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion in U.S. ...
2026-11-05 23:19 · Yahoo
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
2026-11-05 21:30 · Yahoo
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
2026-11-05 21:22 · Yahoo
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
2026-11-05 17:18 · Yahoo
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-05 11:00 · Yahoo
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma
2026-11-04 14:13 · Yahoo
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
2026-11-03 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.